Compare Emerson Electric Co. (EMR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Regeneron Pharmaceuticals Inc — how do they compare? Emerson Electric Co. trades at $159.6 (market cap $88.72B), while Regeneron Pharmaceuticals Inc trades at $745.44 (market cap $76.14B). The key difference: Emerson Electric Co. is the larger of the two by market cap, and Emerson Electric Co. pays the higher dividend (1.4%). Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| EMR | REGN | |
|---|---|---|
Market Cap | $88.72B | $76.14B |
Volume | 2,355,255 | 500,239 |
Sector | Industrials | Health |
52-Week High | $164.38 | $852.03 |
52-Week Low | $123.30 | $557.73 |
Typical Hold Time | 81 Days | 107 Days |
Enterprise Value | $99.80B | $70.85B |
Dividend Yield | 1.4% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $159.22, down 1.34% today, with a bullish technical signal and strong analyst support. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $1.71 exceeding the $1.68 estimate. Revenue growth is steady, projected at $18.6B for 2026, while profitability metrics like a 13.83% net margin and 12.81% ROE reflect operational strength. The stock faces resistance near $160, with support at $158.
Outlook remains positive given earnings momentum and a consensus price target of $165.90, implying ~4% upside. Risks include debt levels rising to 31.26% of assets in 2025 and macroeconomic pressures on industrial demand. Institutional sentiment is bullish, with 53% of analysts rating Buy.
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
